We are live on ! Find out more
ANIX icon

Anixa Biosciences

66 hedge funds and large institutions have $17.6M invested in Anixa Biosciences in 2025 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

56% more call options, than puts

Call options by funds: $67K | Put options by funds: $43K

14% more funds holding

Funds holding: 5866 (+8)

10% more capital invested

Capital invested by funds: $16M → $17.6M (+$1.62M)

0.8% less ownership

Funds ownership: 17.41%16.61% (-0.8%)

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

Holders
66
Holders Change
+8
Holders Change %
+13.79%
% of All Funds
0.87%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
11
Reduced
12
Closed
3
Calls
$67K
Puts
$43K
Net Calls
+$24K
Net Calls Change
-$27K

ANIX Hedge Fund Activity: Q2 2025 in Review

66 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2025, worth a combined $17.6M — up 10% from $16M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ANIX positions and 3 closed out — a net gain of 9 holders — while 11 added to existing stakes and 12 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $203K. The largest seller was Susquehanna International Group, cutting an estimated $510K.

  • 66 institutional investors held Anixa Biosciences (ANIX) as of Q2 2025, up from 58 in Q1 2025.
  • Funds reported $17.6M of Anixa Biosciences stock for Q2 2025, up 10% quarter-over-quarter.
  • 12 funds opened new Anixa Biosciences positions in Q2 2025 and 3 closed out, a net change of +9 holders.
  • The largest Anixa Biosciences buyer in Q2 2025 was Citadel Advisors, an estimated $203K added.
  • The largest Anixa Biosciences seller in Q2 2025 was Susquehanna International Group, an estimated $510K sold.

Based on aggregated 13F filings for Q2 2025.